Physician profile
Kecia Patrease Ford
NPI 1063741023
$7,606.82
in general payments reported to CMS, 2019-2025
28 companies · $1,858 in 2025
The $1,858 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.67 · 2021: $492 · 2022: $1,714 · 2023: $1,059 · 2024: $2,463 · 2025: $1,858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,287 · Education: $93.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,286.73 |
| Education | $93.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $1,020.87 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Amgen INC. | $1,016.90 | 2024-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceutical Holding Company Ltd. | $790.89 | 2022 | |
| Dexcom, INC. | $783.41 | 2023-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Abbvie INC. | $734.65 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $631.18 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $539.23 | 2022-2025 | Ozempic, Rybelsus |
| Global Blood Therapeutics, INC. | $229.22 | 2021-2022 | |
| Mannkind Corporation | $193.10 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $191.33 | 2022-2025 | |
| Exact Sciences Corporation | $188.96 | 2023-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $185.75 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $178.28 | 2020-2023 | Bexsero, Shingrix, Arexvy |
| Abbott Laboratories | $145.94 | 2022-2025 | Freestyle Libre 3 |
| Pfizer INC. | $145.12 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $125.00 | 2024 | |
| Lilly USA, LLC | $112.69 | 2024 | Mounjaro, Zepbound |
| Shield Therapeutics INC | $77.61 | 2023-2024 | Accrufer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $56.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $44.07 | 2024 | Vaxneuvance, Gardasil, Vaxelis |
| Optinose US, INC. | $38.24 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $32.70 | 2022 | |
| Sanofi Pasteur INC. | $27.96 | 2025 | |
| Dynavax Technologies Corporation | $26.45 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $24.41 | 2022 | |
| Sumitomo Pharma America, INC. | $24.11 | 2023 | Myfembree |
| Renalytix Ai, INC. | $23.69 | 2023 | Kidneyintelx Blood Collection Convenience Kit |
| Acarix USA INC. | $18.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kecia Ford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.